These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26329149)

  • 1. [Enzyme Replacement Therapy for Pompe Disease: The Long-Term Efficacy and Limitation].
    Fukuda T; Sugie H
    Brain Nerve; 2015 Sep; 67(9):1091-8. PubMed ID: 26329149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.
    van der Meijden JC; Kruijshaar ME; Harlaar L; Rizopoulos D; van der Beek NAME; van der Ploeg AT
    J Inherit Metab Dis; 2018 Nov; 41(6):1205-1214. PubMed ID: 29556838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.
    Spiridigliozzi GA; Heller JH; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low anal sphincter tone in infantile-onset Pompe Disease: an emerging clinical issue in enzyme replacement therapy patients requiring special attention.
    Tan QK; Cheah SM; Dearmey SM; Kishnani PS
    Mol Genet Metab; 2013 Feb; 108(2):142-4. PubMed ID: 23266370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy and fatigue in adults with Pompe disease.
    Güngör D; de Vries JM; Brusse E; Kruijshaar ME; Hop WC; Murawska M; van den Berg LE; Reuser AJ; van Doorn PA; Hagemans ML; Plug I; van der Ploeg AT
    Mol Genet Metab; 2013 Jun; 109(2):174-8. PubMed ID: 23603069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pompe disease treated with enzyme replacement therapy in pregnancy].
    Grosz Z; Várdi KV; Molnár JM
    Ideggyogy Sz; 2020 Sep; 73(9-10):339-344. PubMed ID: 33035415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.
    Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH
    Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease.
    Ishigaki K; Murakami T; Nakanishi T; Oda E; Sato T; Osawa M
    Brain Dev; 2012 Feb; 34(2):98-102. PubMed ID: 21676566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.
    Kuperus E; Kruijshaar ME; Wens SCA; de Vries JM; Favejee MM; van der Meijden JC; Rizopoulos D; Brusse E; van Doorn PA; van der Ploeg AT; van der Beek NAME
    Neurology; 2017 Dec; 89(23):2365-2373. PubMed ID: 29117951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
    Park JS; Kim HG; Shin JH; Choi YC; Kim DS
    Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle "excessive autophagy" which is relevant to the therapy resistance].
    Fukuda T
    No To Hattatsu; 2010 Mar; 42(2):114-6. PubMed ID: 23858594
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.